FARRAGUT PARTNERS LLP

Lobbying for GILEAD SCIENCES INC. · Pharmaceutical company

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · California · House · Senate · $80,000.00 income · posted Jan 20, 2026

Lobbying activity 2

Medicare/Medicaid

Coverage and reimbursement policy for HCV and HIV portfolios. Issues pertaining to the six protected classes. Drug pricing legislation- part D redesign. Issues related to Medicaid drug rebate program. Monitoring CMMI demonstrations

Health Issues

Issues pertaining to the 340B drug discount program.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.